Impact of Molecular Syndromic Diagnosis of Severe Pneumonia in the Management of Critically Ill Patients

Dimitra Stafylaki, Sofia Maraki, Katerina Vaporidi, Dimitrios Georgopoulos, Dimitrios P. Kontoyiannis, Diamantis P. Kofteridis, Georgios Chamilos

Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Heraklion, Crete, Greece
ICU Department, University Hospital of Heraklion, Heraklion, Crete, Greece
Internal Medicine Department, University Hospital of Heraklion, Heraklion, Crete, Greece
Department of Infectious Diseases, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA

ABSTRACT The impact of syndromic molecular diagnosis in the management of nosocomial infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens has been incompletely characterized. We evaluated the performance of a molecular syndromic platform (BioFire FilmArray-Pneumonia plus Panel) in patients with pneumonia in the intensive care unit (ICU) of a University Hospital in Greece over a 2-year period. We evaluated 79 consecutive patients diagnosed with pneumonia in the ICU (2018–2020), including 55 patients with ventilator associated pneumonia (VAP). We included 40 control patients diagnosed with pneumonia in the ICU the year before the study (2017–2018). We identified 16 cases of VAP due to XDR bacterial pathogens. We found an excellent agreement (89.4% 76/85 reported results) between the results of syndromic platform and conventional cultures of tracheal aspirates. The molecular syndromic test significantly improved time to diagnosis versus conventional culture (3.5 h vs 72 h, P < 0.0001), and identified new pathogens not detected by cultures in 49% of the cases. However, three cases of pneumonia with targets not included in the molecular platform, were not detected. Implementation of the molecular syndromic facilitated treatment modification from broad to narrow spectrum antimicrobial therapy, resulting in significant reductions in antibiotic consumption in the study group compared to the control group, without a negative impact in patient outcome. The implementation of syndromic molecular diagnosis in critically ill patients with pneumonia is associated with timely and improved diagnosis and has significant impact on reduction of antibiotic consumption.

IMPORTANCE The impact of syndromic molecular diagnosis in the management of nosocomial infections caused by MDR/XDR pathogens has been incompletely characterized. We evaluated the performance of a molecular syndromic platform (BioFire FilmArray-Pneumonia plus Panel) in 79 patients with pneumonia in the intensive care unit (ICU) of a University Hospital in Greece over a 2-year period (2018–2020) compared to 40 control patients diagnosed with pneumonia in the ICU the year before the study (2017–2018). Importantly, implementation of syndromic pneumonia panel improved time to diagnosis, identified new pathogens not detected by cultures in 49% of the cases and resulted in a significant reduction in antibiotic consumption compared to the year before initiation of the study without a negative impact in mortality of patients. Collectively, our study demonstrates the positive value of PCR syndromic testing in the management of pneumonia in ICUs high rates of MDR/XDR nosocomial pathogens.

KEYWORDS ICU, severe CAP, syndromic testing, VAP, multidrug resistance, pneumonia

Lower respiratory tract infections remain a leading cause of death worldwide (1). Furthermore, ventilator associated pneumonia (VAP) is a major cause of prolonged length of stay and poor outcome of patients in the Intensive Care Unit (ICU) (2). Timely initiation of
appropriate antibiotic therapy is the most critical determinant of the outcome of patients with severe community acquired pneumonia (CAP), health care associated pneumonia (HAP) and VAP (3). Nonetheless, empirical selection of antimicrobial therapy and optimal management of severe CAP, HAP and VAP is challenging, because of the emergence of multi- and/or pan-drug resistant (MDR/PDR) nosocomial pathogens (4). In particular, infections by Carbapenem resistant Gram-negative bacterial pathogens (e.g., Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) has become an epidemic in many European countries, including Greece (5). Therefore, empirical antibiotic therapy of severe CAP/HAP and VAP typically includes a combination of antibiotics, which is associated with increased toxicity and cost, and selection for antimicrobial resistance.

Molecular syndromic platforms are increasingly utilized in diagnosis of infectious diseases as a mean to improve etiological diagnosis and reduce antibiotic consumption through pathogen-guided empirical antimicrobial therapy (6–10). However, the value of these molecular diagnostics has not been previously tested in the setting of nosocomial infections due to multidrug resistant microbial pathogens. Herein, we evaluated a recently implemented molecular syndromic platform in the management of severe pneumonia in the ICU, in a setting of high rates of antimicrobial resistance. Of interest, implementation of syndromic pneumonia panel improved diagnosis and facilitated de-escalation of antimicrobial therapy, resulting in a significant reduction in antibiotic consumption, compared to the year before initiation of the study.

RESULTS

We enrolled 79 consecutive critically ill patients diagnosed with different type of pneumonia (severe CAP/HAP or VAP) in the ICU and compared them with an historical control group of patients with pneumonia in the ICU during the year before initiation of the study. The demographics and clinical characteristics of both groups of patients are presented in Table 1. VAP comprised almost 2/3 of cases of pneumonia in both study groups (Table 1). There were no significant differences in demographic and clinical characteristics of the patients, including median age, co-morbidities, and severity of illness as evidenced by APACHE II and SOFA score (on day 1). Importantly, we found no significant differences in the outcome, including mean number of days of hospitalization in the ICU and mortality rates, between the two groups of patients (Table 1).

The causative pathogens of pneumonia in the study (syndromic PCR) and control groups identified by conventional cultures are shown in Table 2. In both groups Gram negative nosocomial pathogens including Acinetobacter, Pseudomonas, and Klebsiella species were the main causes of bacterial pneumonia in the ICU. Of interest, there was a trend of increased rates of MDR/XDR causes of pneumonia in the historical control group. Next, we compared the yield of syndromic PCR versus conventional culture of tracheal aspirates in the study group of patients (Fig. 1). We found that the syndromic PCR test (a) was in agreement with culture in 34 patients (40% of cases; Fig. 2 and Table 3) and resulted in correct identification of 29 bacterial pathogens in 19 patients. Accordingly, there was a high degree of concordance (93%; 27/29) between the quantitative culture result (CFU/mL) and the reported semi-quantitative PCR equivalent in these cases (Table 3). Additionally, 44 significant pathogens were exclusively identified by syndromic PCR, which are shown in Table 3. Overall, syndromic PCR provided new information that resulted in improved diagnosis in 42 (49%) of patients with pneumonia (Fig. 2B and C). Nonetheless, in 9 (11%) cases of pneumonia (Fig. 2C), the pathogens were identified only in culture, because the corresponding microbial targets were not included in the syndromic PCR panel; these cases included VAP (n = 3) caused by Gram negative pathogens (Stenotrophomonas maltophilia, Burkholderia spp., Serretia spp.) and 6 co-infections with C. albicans (considered as co-pathogen by the primary physician) (Table 2). Appropriate empirical antimicrobial therapy in bacterial pneumonia not identified by syndromic PCR was guided by Gram stain of the tracheal aspirate.

The syndromic PCR panel correctly identified resistance genes in 12 cases of bacterial pneumonia caused by S. aureus (n = 6), E. coli (n = 4), and Klebsiella spp. (n = 2), in agreement
with the phenotype of susceptibility testing of the corresponding isolates (Table 3). However, the syndromic PCR failed to detect resistance phenotype in other MDR/XDR pathogens including *Pseudomonas* and *Acinetobacter*, which display complex underlying resistance mechanisms. Collectively, in comparison the conventional cultures PCR syndromic test resulted in sharp decrease in time to diagnosis (Fig. 2A) and provided new microbiological information in almost half of the cases of pneumonia (49%) (Fig. 2B and C).

Next, we assessed the impact of syndromic PCR on antibiotic usage by comparing antimicrobial consumption (expressed in DDD/100 BD) in the study group versus the historical control group (Table 4 and Fig. 3). Of interest, we noticed a significant reduction in use of antimicrobials targeting MDR/XDR pathogens, including colistin, tigecycline, and carbapenems (Table 4 and Fig. 3). In parallel, we found a significant increase in use of β-lactam/β-lactamase inhibitors (e.g., ampicillin/sulbactam, piperacillin/sulbactam, and ceftazidime-avibactam) and levofloxacin following implementation of syndromic PCR, which is consistent with antimicrobial de-escalation from broad-spectrum to narrow spectrum antimicrobial therapy. Importantly, the effect of syndromic PCR on reduced consumption of the aforementioned antibiotics was evident across the years of the study (Fig. 3).

**DISCUSSION**

Previous studies demonstrated an excellent performance of syndromic PCR panel in diagnosis of the causative agent of pneumonia compared to conventional microbiological
cultures (14, 15). Of interest, these studies including patients with CAP (14, 15), HAP, or VAP of different disease severity and provided the rationale of use of syndromic PCR as a complementary tool for de-escalation of antimicrobial therapy within the prospect of a dedicated antimicrobial stewardship program (15). However, these studies included a limited number of MDR or XDR pathogens, and a group of patients who did not receive Colistin, Tigecycline and other last resource antimicrobial therapies. Therefore, the feasibility and impact of syndromic PCR in a setting of high prevalence of MDR pathogens has not been previously evaluated.

Herein, we employed a study in ICU patients hospitalized with different types of severe pneumonia (CAP, HAP, VAP) with a need for mechanical ventilation. The majority of these patients (60%) had VAP due to MDR and XDR bacterial pathogens. In contrast to previous studies, we employed a historical control group of patients with pneumonia hospitalized in the ICU during the previous year of the study. Importantly, the control group had comparable

| Microbial pathogen                              | Control group | Syndromic PCR group |
|------------------------------------------------|---------------|---------------------|
| Acinetobacter calcoaceticus-baumanii complex   | 32.5% (n=13)  | 10% (n=10)          |
| Escherichia coli                                | 10% (n=4)     | 5% (n=5)            |
| Klebsiella oxytoca                              | 5% (n=2)      | 1% (n=1)            |
| Klebsiella pneumoniae group                     | 10% (n=4)     | 5% (n=5)            |
| Pseudomonas aeruginosa                         | 22.5% (n=9)   | 6% (n=6)            |
| Proteus mirabilis                               | 7.5% (n=3)    | 3% (n=3)            |
| Enterobacter aerogenes                          | 2.5% (n=1)    | 1% (n=1)            |
| Enterobacter cloacae complex                    | 5% (n=2)      | 5% (n=5)            |
| Haemophilus influenzae                          | 2.5% (n=1)    | 2% (n=2)            |
| Stenotrophomonas maltophilia                   | 7.5% (n=3)    | 1% (n=1)            |
| Serratia marcescens                             | 5% (n=2)      | 0%                  |
| Staphylococcus aureus                           | 12.5% (n=5)   | 11% (n=11)          |
| Streptococcus pneumoniae                        | 5% (n=2)      | 3% (n=3)            |
| Candida albicans                                | 7.5% (n=3)    | 6% (n=6)            |
| Candida tropicalis                              | 2.5% (n=1)    | 0%                  |
| Candida parapsilosis                            | 0%            | 1% (n=1)            |
| No pathogen identified                          | 0%            | 16% (n=16)          |
| Negative (respiratory tract flora)              | 0%            | 21% (n=21)          |
| Burkholderia gladioli                           | 0%            | 1% (n=1)            |
| Serratia rubidiae                               | 0%            | 1% (n=1)            |
| Burkholderia mallei                             | 0%            | 1% (n=1)            |

*There were 3 cases of bacterial pneumonia caused by Stenotrophomonas maltophilia, Serratia, rubidiae, and Burkholderia gladioli exclusively identified by culture (the relevant targets are not included in the PCR panel). In 6 patients with pneumonia, C. albicans was identified in cultures of tracheal aspirate and considered as co-pathogen by the primary physician (target not included in the PCR panel).
clinical and microbiological features with the PCR syndromic group, which allowed to study the impact of the diagnostic platform on antibiotic consumption rates in a relatively unbiased approach. Furthermore, the choice of antimicrobial therapy guided by the PCR result was a decision made by the primary physician (intensivist) following discussion with the primary investigators, rather than by an expert committee (15), a practice that reflects the real use of this diagnostic platform on the daily hospital care. The results of the study clearly validate the use of syndromic PCR in the ICU setting, particularly in the setting of high rates of antimicrobial resistance as a complementary intervention to reduce selection pressure of MDR/XDR pathogens and reduce toxicity associated with the use of broad spectrum empirical antimicrobial therapies. Importantly, comprehensive assessment of the clinical utility of a new syndromic PCR test should evaluate the impact on additional parameters, including length of hospital stay and cost of patient care. Additionally, implementation of antibiotic stewardship substantially improves cost-effectiveness of rapid molecular diagnostic tests in infectious diseases (16) and should be evaluated in future studies on syndromic PCR panel for pneumonia.

Limitations of the study include its retrospective nature, possible changes in infection control and antimicrobial therapy strategies which have not been captured by the investigators of the study (e.g., the impact of the feedback of clinical microbiologist on decisions in empirical antibiotic therapy is difficult to measure), the single center nature of the study and the relatively limited numbers of patients enrolled. Furthermore, the lack of certain nosocomial pathogens (e.g., Stenotrophomonas) in the molecular platform requires increased vigilance and the need for complementarity with other diagnostic procedures (e.g., detection of a broad microbial target such as 16S RNA to indicate the presence of a non-identified pathogen) to ensure optimal patient care. The clinical relevance of detection of microbial causes of VAP at relatively low copy numbers (e.g., corresponding value of 10⁴ CFU/mL) exclusively by syndromic PCR requires validation in future studies. While early report of resistance mechanism in very useful for targeted antibiotic therapy (e.g., KPC versus NDM Klebsiella spp.), the PCR panel does not capture complex resistance mechanisms in certain nosocomial pathogens (e.g., Pseudomonas spp, Acinetobacter) leading to potential misguidance of therapy. Therefore, microbiological cultures remain the gold standard in diagnosis and guidance on targeted therapy in severe bacterial pneumonia. Nonetheless, molecular syndromic platforms should be regarded as important adjunct diagnostic tools for antibiotic stewardship and timely diagnosis of non-culturable pathogens (e.g., viruses). Collectively, our study illustrates that the PCR syndromic approach…

**FIG 2** Comparative analysis of performance of syndromic PCR platform versus conventional culture of tracheal aspirates or BAL related to (A) time to diagnosis, (B) new pathogens identified (C) performance in diagnosis.
### TABLE 3: Analysis of additional pathogens identified by syndromic PCR panel<sup>a</sup>

| Cases                                      | Culture result (CFU/mL) | Syndromic PCR result (corresponding CFU/mL value)<sup>b</sup> |
|--------------------------------------------|-------------------------|-------------------------------------------------------------|
| 1. No Pathogen (culture)                   | Acinetobacter calcoaceticus-baumanii complex (10<sup>6</sup>) |                                                             |
| 2. Klebsiella pneumoniae group (3*10<sup>5</sup>) | Klebsiella pneumoniae group (10<sup>6</sup>), Parainfluenza Virus |                                                             |
| 3. No Pathogen                             | Acinetobacter calcoaceticus-baumanii complex (10<sup>6</sup>) |                                                             |
| 4. Acinetobacter calcoaceticus-baumanii complex (4*10<sup>6</sup>) | Acinetobacter calcoaceticus-baumanii complex (10<sup>6</sup>), Ershchiria coli (10<sup>6</sup>) |                                                             |
| 5. Acinetobacter calcoaceticus-baumanii complex (>10<sup>6</sup>) | Acinetobacter calcoaceticus-baumanii complex (≥10<sup>6</sup>), Parainfluenza Virus |                                                             |
| 6. No Pathogen                             | Human enterovirus/rihovirus                                   |                                                             |
| 7. No Pathogen                             | Respiratory Syncytial Virus                                   |                                                             |
| 8. No Pathogen                             | Respiratory Syncytial Virus                                   |                                                             |
| 9. No Pathogen                             | Influenza A, Respiratory Syncytal Virus                       |                                                             |
| 10. No Pathogen                            | Klebsiella oxytoca (10<sup>6</sup>)                          |                                                             |
| 11. No Pathogen                            | Haemophilus influenza (10<sup>6</sup>)                        |                                                             |
| 12. No Pathogen                            | Haemophilus influenza (10<sup>6</sup>)                        |                                                             |
| 13. No Pathogen                            | Staphylococcus aureus (10<sup>6</sup>)                       |                                                             |
| 14. No Pathogen                            | Pseudomonas aeruginosa (10<sup>6</sup>)                      |                                                             |
| 15. No Pathogen                            | Escherichia coli (10<sup>6</sup>)                            |                                                             |
| 16. Staphylococcus aureus (4*10<sup>6</sup>), Klebsiella pneumoniae group (3*10<sup>6</sup>), Burkholderia gladioli (2*10<sup>6</sup>) | Staphylococcus aureus (≥10<sup>6</sup>), Klebsiella pneumoniae group (10<sup>6</sup>), Haemophilus influenza (10<sup>6</sup>) |                                                             |
| 17. Staphylococcus aureus (25*10<sup>6</sup>) | Staphylococcus aureus (10<sup>6</sup>), Klebsiella pneumoniae group (10<sup>6</sup>) |                                                             |
| 18. Proteus mirabilis (20*10<sup>6</sup>) | Proteus mirabilis (≥10<sup>6</sup>), Haemophilus influenza (≥10<sup>6</sup>) |                                                             |
| 19. Streptococcus pneumoniae (>10<sup>6</sup>) | Streptococcus pneumoniae (≥10<sup>6</sup>, Staphylococcus aureus (10<sup>6</sup>), Streptococcus agalactiae (10<sup>6</sup>) |                                                             |
| 20. Streptococcus pneumoniae (2*10<sup>6</sup>) | Streptococcus pneumoniae (10<sup>6</sup>, Staphylococcus aureus (10<sup>6</sup>, Streptococcus pneumoniae (10<sup>6</sup>, |                                                             |
| 21. Escherichia coli (>10<sup>6</sup>) | Escherichia coli (10<sup>6</sup>), Acinetobacter calcoaceticus-baumanii complex (10<sup>6</sup>, |                                                             |
| 22. Enterobacter cloacae complex (10<sup>6</sup>) | Enterobacter cloacae complex (10<sup>6</sup>, Staphylococcus aureus (10<sup>6</sup>, |                                                             |
| 23. No Pathogen                            | Staphylococcus aureus (10<sup>6</sup>)                        |                                                             |
| 24. Escherichia coli (6*10<sup>6</sup>) | Escherichia coli (10<sup>6</sup>), Moraxella catarrhalis (10<sup>6</sup>) |                                                             |
| 25. No Pathogen                            | Enterobacter cloacae complex (10<sup>6</sup>)                 |                                                             |
| 26. No Pathogen                            | Pseudomonas aeruginosa (10<sup>6</sup>)                      |                                                             |
| 27. Staphylococcus aureus (>10<sup>6</sup>) | Staphylococcus aureus (≥10<sup>6</sup), Acinetobacter calcoaceticus-baumanii complex (10<sup>6</sup>, |                                                             |
| 28. No Pathogen                            | Acinetobacter calcoaceticus-baumanii complex (10<sup>6</sup> |                                                             |
| 29. Staphylococcus aureus (2*10<sup>6</sup>) | Staphylococcus aureus (≥10<sup>6</sup>, Influenza A            |                                                             |
| 30. Acinetobacter calcoaceticus-baumanii complex (>10<sup>6</sup>, Pseudomonas aeruginosa (2*10<sup>6</sup>), Klebsiella pneumoniae group (40*10<sup>6</sup>) | Acinetobacter calcoaceticus-baumanii complex (≥10<sup>6</sup), Pseudomonas aeruginosa (10<sup>6</sup>, Klebsiella pneumoniae group (10<sup>6</sup>, Coronavirus |                                                             |
| 31. Escherichia coli (4*10<sup>6</sup>, Proteus mirabilis (80*10<sup>6</sup>) | Escherichia coli (≥10<sup>6</sup>), Proteus mirabilis (≥10<sup>6</sup>, Acinetobacter calcoaceticus-baumanii complex (≥10<sup>6</sup>, |                                                             |
| 32. Klebsiella pneumoniae group (5*10<sup>6</sup>, Klebsiella oxytoca (2*10<sup>6</sup>) | Klebsiella pneumoniae group (10<sup>6</sup>), Klebsiella oxytoca (10<sup>6</sup>, Staphylococcus aureus (10<sup>6</sup>, |                                                             |
| 33. No Pathogen                            | Haemophilus influenza (10<sup>6</sup>)                        |                                                             |
| 34. No Pathogen                            | Serratia marcescens (10<sup>6</sup>, Klebsiella oxytoca (10<sup>6</sup>, |                                                             |
| 35. Acinetobacter calcoaceticus-baumanii complex (10<sup>6</sup>) | Acinetobacter calcoaceticus-baumanii complex (≥10<sup>6</sup>, Escherichia coli (10<sup>6</sup>, |                                                             |
| 36. Streptococcus pneumoniae (>10<sup>6</sup>) | Streptococcus pneumoniae (≥10<sup>6</sup>, Haemophilus influenza (10<sup>6</sup), Moraxella catarrhalis (10<sup>6</sup), Proteus mirabilis (10<sup>6</sup), |                                                             |
| 37. No Pathogen                            | Staphylococcus aureus (10<sup>6</sup>, Haemophilus influenza (10<sup>6</sup), |                                                             |
| 38. No Pathogen                            | Acinetobacter calcoaceticus-baumanii complex (10<sup>6</sup> |                                                             |
| 39. Candida albicans (10<sup>6</sup>) | Enterobacter cloacae complex (10<sup>6</sup>, Escherichia coli (10<sup>6</sup), |                                                             |
| 40. No Pathogen                            | Acinetobacter calcoaceticus-baumanii complex (≥10<sup>6</sup>) |                                                             |
| 41. Haemophilus influenza (2*10<sup>6</sup>, Burkholderia mallei (10<sup>6</sup>) | Haemophilus influenza (≥10<sup>6</sup), Moraxella catarrhalis (≥10<sup>6</sup), |                                                             |
| 42. No Pathogen                            | Legionella pneumophila                                         |                                                             |

<sup>a</sup>There were 34 cases of bacterial pneumonia with agreement between syndromic PCR and culture results, including 15 cases with no pathogen identified and 19 cases of concordant identification of bacterial pathogens (7 Staphylococcus aureus, 4 Pseudomonas aeruginosa, 3 Acinetobacter calcoaceticus-baumanii complex, and 6 bacterial co-infections). Co-infections included 1 case of Enterobacter cloacae complex plus Klebsiella pneumoniae group; 1 case of Acinetobacter calcoaceticus-baumanii complex plus Pseudomonas aeruginosa; 1 case of Staphylococcus aureus plus Enterobacter cloacae complex and Proteus mirabilis; 1 case of Staphylococcus aureus plus Pseudomonas aeruginosa; 1 case of Staphylococcus aureus plus Enterobacter cloacae complex; and 1 case of Escherichia coli, Klebsiella aerogenes. In all 19 cases of bacterial pneumonia with concordant identification of the pathogen, there was excellent agreement (38/40, 95%) between the quantitative culture result reported in CFU/mL and the semi-quantitative result of the syndromic PCR reported as CFU/mL equivalent gene copy numbers. In two cases syndromic PCR underestimated the bacterial burden compared to microbiological culture (Enterobacter aerogenes 10<sup>6</sup> vs. 2 × 10<sup>6</sup> CFU/mL; Pseudomonas aeruginosa 10<sup>6</sup> vs. 2 × 10<sup>6</sup> CFU/mL).

<sup>b</sup>The syndromic PCR panel identified 12 cases with resistance genes; 9 of them (5 cases of Staphylococcus aureus mecA/C and MREJ, 2 cases of Escherichia coli CXT-M, 1 case of Escherichia coli KPC, and 1 case of Klebsiella pneumoniae KPC) were in agreement with the phenotype in susceptibility testing of the isolate. In 3 additional cases PCR detected additional resistance genes (Klebsiella CXT-M, Staphylococcus aureus mecA/C and MREJ, Escherichia coli VIM). Detection of resistance genes was not considered as an indication of improved diagnosis, because in several cases of MDR/XDR pathogens with complex resistance mechanisms (e.g., Pseudomonas, Acinetobacter) the resistance phenotype was not identified by syndromic PCR.
is a useful tool in the management of pneumonia in the ICU, especially in the nosocomial setting of high rates of MDR/XDR nosocomial pathogens.

## MATERIALS AND METHODS

### Study participants

Between June 2018 and June 2020 all patients admitted the ICU of University Hospital of Heraklion, Crete with severe CAP/HAP or those who developed VAP during ICU stay were eligible for enrollment to the study. The following criteria were required for patient inclusion: (1) age ≥ 18 years, (2) presence of clinical and radiological criteria for pneumonia according to the IDSA guidelines: new lung infiltrate on a chest X-ray and evidence that the infiltrate was of an infectious origin, i.e., at least two of three clinical features (fever greater than 38°C, leukocytosis or leukopenia, and purulent secretions), and (3) severe respiratory failure requiring mechanical ventilation.

### TABLE 4 Comparative analysis of antibiotic consumption in control and syndromic PCR group of patients expressed as DDD/100 bed days (BD) values

| Antibiotic                  | Control group (DDDs/100BD) | Syndromic PCR group (DDDs/100BD) | P value |
|-----------------------------|----------------------------|----------------------------------|---------|
| Ampicillin/sulbactam        | 6.7                        | 13.22                            | 0.1177  |
| Piperacillin tazobactam     | 11.96                      | 33.02                            | 0.0003  |
| Ceftazidime–Avibactam       | 3.14                       | 13.23                            | 0.0091  |
| Ceftazidime                 | 2.6                        |                                  |         |
| Ceftriaxone                 | 2.49                       | 0.52                             | 0.9999  |
| Cefepime                    | 14.97                      | 16.63                            | 0.5875  |
| Meropenem                   | 67.22                      | 23.61                            | <0.0001 |
| Levofoxacine                | 5.3                        | 17.64                            | 0.0027  |
| Ciprofloxacin               | 4.99                       | 2.67                             | 0.728   |
| Colistin<sup>a</sup>        | 94.86                      | 51.91                            | 0.0011  |
| Vancomycin                  | 10.91                      | 16.63                            | 0.1772  |
| Tigecycline                 | 69.44                      | 32.36                            | 0.0008  |
| Gentamycin                  | 5.13                       | 1.14                             | 0.2203  |
| Daptomycin                  | 32.74                      | 50.49                            | 0.0137  |
| Amikacin                    | 2.08                       | 3.13                             | 0.6718  |
| Clindamycin                 | 0.69                       | 0.65                             | 0.9999  |
| Linezolid                   | 11.54                      | 12.37                            | 0.8373  |
| Trimethoprim sulfoxethoxazol| 4.44                       | 2.69                             | 0.9999  |
| Metronidazol                | 1.25                       | 1.41                             | 0.9999  |
| Itraconazole                | 0.21                       | 4.98                             | 0.0234  |
| Fluconazole                 | 0.73                       | 1.3                              | 0.9999  |
| Isavuconazole               | 1.62                       |                                  |         |
| Amphotericin B              | 4.65                       |                                  |         |
| Micafungin                  | 2.29                       | 16.41                            | 0.0004  |
| Anidulafungin               | 4.99                       | 5.73                             | 0.7639  |
| Oseltamivir                 | 1.75                       |                                  |         |
| Cefolozan tazobactam        | 1.04                       | 1.56                             | 0.6057  |
| Tobramycin                  | 0.65                       |                                  |         |
| Acyclovir                   | 1.06                       |                                  |         |
| Azithromycin                | 0.26                       |                                  |         |
| Isoniazid                   | 0.85                       |                                  |         |
| Ceftaolin fosamil           | 2.34                       |                                  |         |
| Voriconazole                | 0.13                       |                                  |         |
| Mosfloxacin                 | 0.13                       |                                  |         |

<sup>a</sup>There were 15 cases of pneumonia in the control group and 33 cases of pneumonia in the PCR group that received appropriate therapy with piperacillin-tazobactam.

<sup>b</sup>There were 2/40 and 19/79 patients with pneumonia in the control and syndromic PCR groups who received Ceftazidime-Avibactam, respectively. These included 1 case of carbapenem resistant *Klebsiella pneumoniae* in the control group, 8 cases of *Acinetobacter baumannii* (2 PDR and 6 XDR) and 2 cases of carbapenem resistant (KPC) *Klebsiella pneumoniae* in the PCR group.

<sup>c</sup>Examples of de-escalation due to discontinuation of colistin in VAP include (a) a patient with MRSA pneumonia (*S. aureus*, detection of mecA/C-MREJ resistance genes) who received empirical antimicrobial therapy with colistin plus piperacillin-tazobactam and following PCR result the treatment was modified to linezolid/cefepime (b) a patient with pneumonia caused by *Enterobacter cloacae* on empirical therapy with colistin plus piperacillin-tazobactam who received piperacillin-tazobactam following the PCR result, and (c) a patient of mixed infection by *Enterobacter aerogenes* plus *Klebsiella pneumoniae* on empirical therapy with meropenem/colistin who received piperacillin-tazobactam following the PCR result. In addition to de-escalation, targeted antimicrobial therapy was started upfront based on the PCR report in several cases of pneumonia (e.g., influenza, *Legionella*).

<sup>d</sup>Not applicable.
failure requiring ICU admission and mechanical ventilation. Criteria for pneumonia were retrospectively evaluated by two clinical investigators (K.V., and D.G.). Severe CAP or HAP requiring ICU admission, and VAP were included. HAP was defined as pneumonia occurring ≥ 48 h after admission, which was not incubating at the time of admission and not associated with medical ventilation (11, 12). VAP referred to pneumonia occurring ≥ 48 h after endotracheal intubation (11). CAP included all episodes of pneumonia acquired outside of the hospital setting. The presence of immunodeficiency, malignancy or other co-morbidity was not considered as an exclusion criterion. All intubations were performed according to “American Journal of respiratory and critical care medicine” (13). Endotracheal aspirates were obtained from all the patients at the time of clinical indication of pneumonia and tested simultaneously, using conventional microbiological techniques and the PCR BioFire FilmArray Pneumonia Panel (bioMérieux S.A., France). The following targets are included in the following technic of antimicrobial resistance. Detailed information on the susceptibility of the predominant causes of pneumonia, Legionella pneumophila, Mycoplasma pneumoniae, Adenovirus, Coronavirus, Human metapneumovirus, Human rhinovirus/enterovirus, Influenza A virus, Influenza B virus, Parainfluenza virus, Respiratory syncytial virus, CTX-M, KPC, NDM, Oxa48-like, VM, IMP, mecA/meC, and MREJ.

Exclusion criteria included (i) ICU patients with fever of another etiology, (ii) colonization of the lung or ventilator associated tracheobronchitis (VAT), (iii) patient already enrolled in the study, and (iv) patients on palliative care.

**Microbiology methods.** Endotracheal aspirate (EA) samples with <10 epithelial cells per low power field on Gram-stained smears were acceptable for culture (3). The respiratory samples (EA and bronchoalveolar lavage (BAL) fluid) were quantitatively cultured for aerobic microorganisms using chocolate agar, sheep blood agar, and MacConkey agar plates. Plates were incubated overnight in a 5% CO₂ atmosphere at 35°C for 48 h. Colonies were then counted and bacterial concentrations (CFU/mL) were calculated. Diagnostic thresholds of ≥ 10⁴ CFU/mL and ≥ 10⁵ CFU/mL were adopted for BAL cultures and EA, respectively; bacteria grown in numbers < 10⁴ CFU/mL were not reported as a relevant cause of pneumonia (3). Pure cultures and dominant pathogens were identified by the VITEK2 system (bioMérieux). Diagnostic tests for viruses and atypical bacteria were not conducted routinely. Respiratory samples were simultaneously tested upon receipt with the BioFire FilmArray Pneumonia Panel according to the manufacturer’s instructions directly on native respiratory samples.

**Clinical data.** Clinical and demographical characteristics were retrospectively obtained from the electronic medical records of each patient. Investigators collected demographic characteristics (age, gender) and medical data including comorbidities, classification of pneumonia (VAP, HAP, or CAP), severity scores, antibiotics prescribed, and outcome. For each episode, the result of the syndromic PCR was presented to the primary physician on call (intensivist) and the primary investigators of the study (D.S., G.C., K.V.) in real time. The clinical microbiologist in charge of the study (D.S.) provided explanation on the results of the syndromic PCR test to the primary physician, including discussion on antibiotic choices based on detected pathogen and the results of the genetic markers of antimicrobial resistance. Detailed information on the susceptibility of the predominant causes of VAP in the ICU (e.g., Pseudomonas, Klebsiella spp.) in the year before the study was provided to all participating physicians. The primary physician decided on the most appropriate antimicrobial therapy for each pneumonia episode.

**Endpoints.** Primary aim of the study was to evaluate the rationale for broad use of BIOFIRE FILMARRAY Pneumonia Panel in routine management of severe CAP/HAP and VAP in hospitals with high rates of MDR and pan-drug-resistant (PDR) bacterial pathogens. To address this endpoint, we performed comparative analysis of the rates of antimicrobial consumption in ICU patients with pneumonia the year before (2018; historical control group) and over the study period (2018–2020). Rates of antibiotic consumption were expressed as defined daily dose (DDD) per 100 bed days (14).
Additionally, the following measures were assessed: The accuracy of multiplex PCR compared to routine microbiological diagnosis, the decrease in time to diagnosis associated with the use of multiplex PCR; the impact of molecular diagnosis on establishment of etiological diagnosis of severe pneumonia and VAP; the effect of rapid molecular diagnostic result on the outcome of patients, defined by days of ICU hospitalization and overall mortality.

Statistical analysis. All data were anonymously collected and stored on a secured database. Two-sided unpaired Student’s t test was used for statistical comparisons of continuous variables between the two groups. Fisher’s exact test was used for analysis of categorical variables. P < 0.05 was considered statistically significant. Analysis was performed using the GraphPad Prism software (version VII). The study was approved by the Ethics Committee of the University of Crete (IRB approval # 58/16.07.2020).

The data sets used during the current study are available from the corresponding author on reasonable request.

ACKNOWLEDGMENTS

This study was supported by an Investigator Initiated Study sponsored by Bio-Mérieux.

Georgios Chamilos conceived and supervised the study, and wrote the manuscript along with comments from coauthors. Dimitra Stafylaki performed all the microbiological studies, collected and analyzed data and participated in the writing of the manuscript. Sofia Maraki performed the clinical protocol and analyzed data; Katerina Vaponidi and Dimitrios Georgopoulos participated in patient recruitment and data analysis Dimitrios P. Kontoyiannis and Diamantis P. Kofferidis analyzed data and participated in writing of the manuscript.

We have no conflicting financial interests in this work other than the sponsorship of the study.

REFERENCES

1. Torres A, Cilloin C, Niederan MS, Menéndez R, Chalmers JD, Wunderink RG, van der Poll T. 2021. Wunderink RG, van der Poll T. Pneumonia. Nat Rev Dis Primers 7:25. https://doi.org/10.1038/s41572-021-00259-0.
2. Bebauer M, Timat JF, Vansteelandt S, Depuydt P, Vézin A, Garrouste-Orgeas M, Decruyenaere J, Clec H, Azoulay E, Benoit D, Outcomes Study Group. 2011. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med 184:1133–1139. https://doi.org/10.1164/rcrm.201105-0867OC.
3. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. 2002. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122:262–268. https://doi.org/10.1378/chest.122.1.262.
4. Depuydt PO, Vandijck DM, Bebauer MA, Decruyenaere JM, Blot SJ, Vogelaers DP, Benoit DD. 2008. Impact of multidrug antibiotic resistance in pathogens causing ventilator-associated pneumonia. Crit Care 12:R142. https://doi.org/10.1186/cc7119.
5. Tsolitsis C, Kritisotakis EI, Karageorgos SA, Stratakou S, Psarologakis C, Koki S, Sikas A. 2016. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients. Int J Antimicrob Agents 48:492–497. https://doi.org/10.1016/j.ijantimicag.2016.07.007.
6. Ramanan P, Bryson AL, Binnicker MJ, Pitts BS, Patel R. 2017. Syndromic panel-based testing in clinical microbiology. Clin Microbiol Rev 31:1–28.
7. Bauer KA, Perez VK, Forrest GN, Goff DA. 2014. Review of rapid diagnostic tests used by antimicrobial stewardship programs. Clin Infect Dis 59:513–514. https://doi.org/10.1093/cid/ciu547.
8. Buchan BW, Windham S, Balada-Llasat JM, Leber A, Harrington A, Relich R, Murphy C, Dierd B, Naccache S, Ronen S, Hopp A, Mahmutoglu D, Faron ML, Ledeboer NA, Carroll A, Stone H, Akerele O, Everhart K, Kornwit A, Kwong C, Buckner R, Warren D, Fowler R, Chandersekaran S, Huse H, Campeau S, Humphries R, Gause C, Huang A. 2020. Practical Comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on Antimicrobial Stewardship in Adult Hospitalized Patients with Lower Respiratory Tract Infections. J Clin Microbiol 58:e01934-17. https://doi.org/10.1128/JCM.01934-17.
9. Gadsby NJ, Russell CD, McHugh MP, Mark H, Conway Morris A, Laureson IF, Hill AT, Templeton KE. 2016. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis 62:817–823. https://doi.org/10.1093/cid/civ1214.
10. Monard C, Pehlivan J, Auger G, Alviset S, Tran Dinh A, Duqueir P, Gastli N, d’Humières C, Maamor A, Boibieux A, Baldeyrou M, Loubinoux J, Dauwalder O, Cattoir V, Armand-Lefèvre L, Kernéis S, ADAPT study group. 2020. Multicenter evaluation of a syndromic rapid multiplex PCR test for early adaptation of antimicrobial therapy in adult patients with pneumonia. Crit Care 24:434. https://doi.org/10.1186/s13054-020-03114-y.
11. Kalil AC, Metzky ML, Kompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O’Grady NP, Bartlett JG, Carratala J, El Solh AA, Ewig S, Fey PD, File TM, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. 2016. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63:e61–e111. https://doi.org/10.1093/cid/ciw353.
12. American Thoracic Society; Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med American Thoracic Society - AJRCCM 171:388–416. https://doi.org/10.1164/rcrm.200405-6445T.
13. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crotthers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metzky ML, Musher DM, Restrepo MI, Whitney CG. 2019. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 200:e45–e67. https://doi.org/10.1164/rcrm.201908-1581ST.
14. Humphries RM, Ambler J, Mitchell SL, Castanheira M, Dingle T, Hindler JA, Keoth L, Kei K, Hardy D, Zimmer B, Butler-Wu S, Dierd B, Pisci B, Shawar D, Dingle T, Humphries R, Sei K, Koeth L. 2018. CLSI Methods Development and Standardization Working Group of the Subcommittee on Antimicrobial Susceptibility Testing. CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests. J Clin Microbiol 56:e01934-17. https://doi.org/10.1128/JCM.01934-17.
15. Hekster YA, Vree TB, Goris RJ, Boerema JB. 1982. The effects of guidelines and audit on antimicrobial drug use. J Clin Hosp Med 200:e45–e67. https://doi.org/10.1164/rcrm.200405-6445T.
16. Pliakos EE, Andreatos N, Shehadeh F, Ziakas PD, Mylonakis E. 2018. The effects of guidelines and audit on antimicrobial drug use in a university hospital. A retrospective study of the effects of guidelines and audit on antimicrobial drug use. J Clin Hosp Pharm 7:251–260. https://doi.org/10.1111/j.1365-3710.1982.tb01030.x.
17. Plakos EE, Andreatos N, Shehadeh F, Ziakas PD, Mylonakis E. 2018. The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship. Clin Microbiol Rev 31:e00095-17. https://doi.org/10.1128/CMR.00095-17.